Literature DB >> 33712975

Endocannabinoid and dopaminergic system: the pas de deux underlying human motivation and behaviors.

A A A Putri Laksmidewi1, Andreas Soejitno2.   

Abstract

Endocannabinoid system (ECS) has been identified ever since cannabinoid, an active substance of Cannabis, was known to interact with endogenous cannabinoid (endocannabinoid/eCB) receptors. It later turned out that eCB was more intricate than previously thought. It has a pervasive role and exerts a multitude of cellular signaling mechanisms, regulating various physiological neurotransmission pathways in the human brain, including the dopaminergic (DA) system. eCB roles toward DA system were robust, clearly delineated, and reproducible with respect to physiological as well as pathological neurochemical and neurobehavioral manifestations of DA system, particularly those involving the nigrostriatal and mesocorticolimbic pathways. The eCB-DA system regulates the basics in the Maslow's pyramid of hierarchy of needs required for individual survival such as food and sexual activity for reproductive purpose to those of higher needs in the pyramid, including self-actualization behaviors leading to achievement and reward (e.g., academic- and/or work-related performance and achievements). It is, thus, interesting to specifically discuss the eCB-DA system, not only on the molecular level, but also its tremendous potential to be developed as a future therapeutic strategy for various neuropsychiatric problems, including obesity, drug addiction and withdrawal, pathological hypersexuality, or low motivation behaviors.

Entities:  

Keywords:  Clinical implications; Dopaminergic system; Endocannabinoid system; Molecular mechanisms; Neurobehavior

Year:  2021        PMID: 33712975     DOI: 10.1007/s00702-021-02326-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  153 in total

1.  Attenuation of morphine antinociceptive tolerance by cannabinoid CB1 and CB2 receptor antagonists.

Authors:  Ahmet Altun; Kemal Yildirim; Ercan Ozdemir; Ihsan Bagcivan; Sinan Gursoy; Nedim Durmus
Journal:  J Physiol Sci       Date:  2015-04-18       Impact factor: 2.781

2.  Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D2 autoreceptors.

Authors:  Estefanía P Bello; Yolanda Mateo; Diego M Gelman; Daniela Noaín; Jung H Shin; Malcolm J Low; Verónica A Alvarez; David M Lovinger; Marcelo Rubinstein
Journal:  Nat Neurosci       Date:  2011-07-10       Impact factor: 24.884

Review 3.  The Lateral Habenula Circuitry: Reward Processing and Cognitive Control.

Authors:  Phillip M Baker; Thomas Jhou; Bo Li; Masayuki Matsumoto; Sheri J Y Mizumori; Marcus Stephenson-Jones; Aleksandra Vicentic
Journal:  J Neurosci       Date:  2016-11-09       Impact factor: 6.167

Review 4.  The physiology, signaling, and pharmacology of dopamine receptors.

Authors:  Jean-Martin Beaulieu; Raul R Gainetdinov
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

5.  Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step.

Authors:  Louise Adermark; David M Lovinger
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

6.  Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity.

Authors:  Louise Adermark; Giuseppe Talani; David M Lovinger
Journal:  Eur J Neurosci       Date:  2009-01       Impact factor: 3.386

7.  Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum.

Authors:  David Belin; Barry J Everitt
Journal:  Neuron       Date:  2008-02-07       Impact factor: 17.173

Review 8.  Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.

Authors:  Katia Befort
Journal:  Front Pharmacol       Date:  2015-02-05       Impact factor: 5.810

Review 9.  The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review.

Authors:  Albert Batalla; Hella Janssen; Shiral S Gangadin; Matthijs G Bossong
Journal:  J Clin Med       Date:  2019-07-19       Impact factor: 4.241

10.  Preliminary evaluation of the efficacy, safety, and costs associated with the treatment of chronic pain with medical cannabis.

Authors:  Terrance Bellnier; Geoffrey W Brown; Tulio R Ortega
Journal:  Ment Health Clin       Date:  2018-04-26
View more
  1 in total

Review 1.  Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition.

Authors:  Alessandro Papa; Silvia Pasquini; Chiara Contri; Sandra Gemma; Giuseppe Campiani; Stefania Butini; Katia Varani; Fabrizio Vincenzi
Journal:  Cells       Date:  2022-01-29       Impact factor: 6.600

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.